1159598-21-6 Usage
Description
(R)-2-hydroxymethylpiperazine-1,4-dicarboxylic acid di-tert-butyl ester, also known as HMPD-TBE, is a chemical compound derived from piperazine with a unique structure featuring two carboxylic acid groups and a hydroxyl group. It is widely utilized in organic synthesis and pharmaceutical research due to its ability to modify the properties of other molecules, making it a valuable tool in drug discovery.
Uses
Used in Pharmaceutical Research:
HMPD-TBE is used as a building block in the synthesis of various pharmaceutical compounds. Its unique structure allows it to modify the properties of other molecules, making it a valuable tool in the development of new drugs and biologically active compounds.
Used in Asymmetric Synthesis:
HMPD-TBE is used as a chiral ligand in asymmetric synthesis, playing a significant role in the production of enantiomerically pure chemicals. This application is crucial for the creation of high-quality pharmaceuticals and other compounds that require specific stereochemistry for their intended use.
Used in Organic Synthesis:
HMPD-TBE is employed in organic synthesis as a versatile building block, contributing to the development of a wide range of chemical compounds with various applications across different industries.
Check Digit Verification of cas no
The CAS Registry Mumber 1159598-21-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,1,5,9,5,9 and 8 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1159598-21:
(9*1)+(8*1)+(7*5)+(6*9)+(5*5)+(4*9)+(3*8)+(2*2)+(1*1)=196
196 % 10 = 6
So 1159598-21-6 is a valid CAS Registry Number.
1159598-21-6Relevant articles and documents
KRAS G12C INHIBITORS AND USES THEREOF
-
Page/Page column 113; 122, (2020/12/07)
The invention relates to compounds of Formula I, and pharmaceutically acceptable salts thereof, and methods of making and using the same. The compounds of the invention are effective in inhibiting KRAS protein with a G12C mutation and are suitable for use in methods of treating cancers mediated, in whole or in part, by KRAS G12C mutation.
